AIM ImmunoTech Inc. announced it has entered into exchange agreements to convert a portion of an outstanding promissory note into equity. The company settled approximately $400,000 of debt by issuing 1,749,434 shares of its common stock to the lender, Streeterville Capital, LLC.
Key Details
- Transaction Value: Approximately $400,000 of a Promissory Note dated November 18, 2025, was converted into 1,749,434 common shares.
- Conversion Price: The exchange was executed at an average conversion price of approximately $0.228 per share.
- Agreement Dates: The exchange agreements were entered into between September 8, 2026, and September 9, 2026, following stockholder approval obtained on July 15, 2026.